Abstract
2011 was a landmark year in the therapy for metastatic melanoma as it was the year that both Ipilmumab and Vemurafenib were approved by the FDA. Preceding this lay many years of frustration with no improvement in survival rates for 40 years. The prior standard therapy consisted of two main options, dacarbazine a non classic alkylating agent approved in the 1970s on the basis of overall response rates but having no benefit on survival and high dose IL2, approved in 1998 on the basis of durable complete response in a minority of patients. Thus the survival rates of patients with metastatic melanoma had remained largely unchanged since the 1970s with a median overall survival of 6 to 9 months. Metastatic melanoma is responsible for more than 75% of deaths from all forms of skin cancer, yet only represents less than 5% of all skin cancer diagnosis [1]. It is the most aggressive form of skin cancer and it is estimated that 76, 250 patients will be diagnosed in the United States in 2012 with 9,180 deaths [2]. The fruition of immunological and molecular research Ipilimumab, a CTLA4 antibody and Vemurafenib, a BRAF inhibitor in patients with BRAF mutation, have shown significant improvements in overall survival. With more targeted therapy options on the horizon these are significant times of hope for a disease which has proved so elusive in the past and has grown dramatically in incidence and annual mortality during the last few decades [3, 4]. This review will describe these new advances in targeted molecular and immunological therapies on the background of older therapies and also look at potential future therapy targets.
Keywords: BRAF inhibitors, Ipilimumab, MAPK pathway, MEK inhibitors, Metastatic melanoma, P13K/AKT pathway, somatic mutations.
Current Cancer Therapy Reviews
Title:Current Advances in Therapy for Metastatic Melanoma
Volume: 9 Issue: 1
Author(s): Elaine O’Donoghue, Dalia Kamel and Bryan T. Hennessy
Affiliation:
Keywords: BRAF inhibitors, Ipilimumab, MAPK pathway, MEK inhibitors, Metastatic melanoma, P13K/AKT pathway, somatic mutations.
Abstract: 2011 was a landmark year in the therapy for metastatic melanoma as it was the year that both Ipilmumab and Vemurafenib were approved by the FDA. Preceding this lay many years of frustration with no improvement in survival rates for 40 years. The prior standard therapy consisted of two main options, dacarbazine a non classic alkylating agent approved in the 1970s on the basis of overall response rates but having no benefit on survival and high dose IL2, approved in 1998 on the basis of durable complete response in a minority of patients. Thus the survival rates of patients with metastatic melanoma had remained largely unchanged since the 1970s with a median overall survival of 6 to 9 months. Metastatic melanoma is responsible for more than 75% of deaths from all forms of skin cancer, yet only represents less than 5% of all skin cancer diagnosis [1]. It is the most aggressive form of skin cancer and it is estimated that 76, 250 patients will be diagnosed in the United States in 2012 with 9,180 deaths [2]. The fruition of immunological and molecular research Ipilimumab, a CTLA4 antibody and Vemurafenib, a BRAF inhibitor in patients with BRAF mutation, have shown significant improvements in overall survival. With more targeted therapy options on the horizon these are significant times of hope for a disease which has proved so elusive in the past and has grown dramatically in incidence and annual mortality during the last few decades [3, 4]. This review will describe these new advances in targeted molecular and immunological therapies on the background of older therapies and also look at potential future therapy targets.
Export Options
About this article
Cite this article as:
O’Donoghue Elaine, Kamel Dalia and Hennessy T. Bryan, Current Advances in Therapy for Metastatic Melanoma, Current Cancer Therapy Reviews 2013; 9 (1) . https://dx.doi.org/10.2174/1573394711309010002
DOI https://dx.doi.org/10.2174/1573394711309010002 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design Inhibition of Protein N-Myristoylation: A Therapeutic Protocol in Developing Anticancer Agents
Current Cancer Drug Targets Decreased lncRNA SNHG16 Accelerates Oxidative Stress Induced Pathological Angiogenesis in Human Retinal Microvascular Endothelial Cells by Regulating miR-195/mfn2 Axis
Current Pharmaceutical Design Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Pleural Involvement Due to Metastatic Melanoma: A Rare Complication and Literature Review
Current Respiratory Medicine Reviews Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry Melanoma
Current Cancer Therapy Reviews Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer
Current Cancer Drug Targets Endoglin Silencing has Significant Antitumor Effect on Murine Mammary Adenocarcinoma Mediated by Vascular Targeted Effect
Current Gene Therapy Current Non-viral siRNA Delivery Systems as a Promising Treatment of Skin Diseases
Current Pharmaceutical Design Targeted Inhibition of AKT in Pancreatic Cancer
Current Cancer Therapy Reviews Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Cyclooxygenase Enzymes: Regulation and Function
Current Pharmaceutical Design Efalizumab: A Biological Agent for the Treatment of Psoriasis
Reviews on Recent Clinical Trials Vitamin D, Sunlight, and the Epidemiology of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Quantitative Structure-Wavelength Relationship Modeling of Porphin -Derivative Photosensitizers
Combinatorial Chemistry & High Throughput Screening